Mistake 1: No Regulatory Pathway Clarity
Healthcare investors evaluate regulatory risk first. Founders who can't clearly explain their FDA pathway (510(k), De Novo, PMA, or exempt), HIPAA compliance framework, and timeline lose credibility immediately.
Fix: Have a one-page regulatory strategy document ready before investor conversations. Include: classification, pathway, timeline, key milestones, and cost estimates. If you don't need FDA clearance, explain why clearly.
Mistake 2: No Reimbursement Strategy
A healthcare product that works clinically but can't get reimbursed by insurance is a product without a market. Investors ask: 'Who pays?' If the answer is unclear, they pass.
Fix: Map your reimbursement pathway — existing CPT codes, payer coverage, out-of-pocket pricing model, or value-based contract structure. Even early-stage companies should have a hypothesis for how the economics work at scale.
Mistake 3: Leading with Clinical Data, Not Business Model
Clinical outcomes matter — but investors fund businesses, not clinical studies. A founder who spends 20 minutes on clinical efficacy data and 5 minutes on go-to-market strategy has the priorities reversed.
Fix: Lead with the business problem and the customer's willingness to pay. Use clinical data to support the business case, not replace it. Structure: market opportunity → business model → clinical evidence → regulatory pathway → team → ask.
Mistake 4: Ignoring Sales Cycle Length
Healthcare sales cycles are 6-18 months for enterprise deals. Founders who project revenue growth based on SaaS timelines (1-3 month sales cycles) present financial models that experienced healthcare investors immediately dismiss.
Fix: Build realistic revenue projections that account for healthcare sales dynamics: longer pilots, compliance reviews, committee approvals, and integration timelines. Show investors you understand these realities and have built them into your capital needs.
Ready to Position Before You Pitch?
The Strategic Capital Review is a 30-minute call to assess your raise readiness and determine whether access to our investor network is relevant to your situation.
Schedule Your Review